My thoughts are that the concentration of RECAF in the blood is different from one individual to another. The concentration also varies within the same individual over time. This is why the press release indicated that it is necessary to establish a RECAF baseline for an individual through sequential blood tests in order to use RECAF to detect cancer at the earliest stages.
Here is an interesting quote from the Annual Report for the year ending December 31, 2005 and filed with the SEC on March 30, 2006:
"As a result, since March 2002 BioCurex's research and development efforts have been focused on the development of a serum-based screening assay based upon BioCurex's RECAF technology." "BioCurex believes that a significant market exists for a screening assay which can detect multiple cancers from a blood (serum) sample."
The conclusion seems to be this sentence from the May 16, 2006 press release: "We do not know yet if the normal RECAF concentration is constant enough to make this personalization possible." kag
News 
Market Data 
Discover 
